NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Soligenix's Clinical Trial Progress and Zacks Report Analysis
TL;DR
Soligenix's 48% response rate in its Phase 3 trial for HyBryte presents a potential investment advantage with a $25 per share valuation despite muted market reaction.
Zacks' $25 valuation for Soligenix uses a probability-adjusted discounted cash flow model based on the Phase 3 trial's 48% blinded response rate and 50-patient enrollment milestone.
Soligenix's HyBryte trial progress offers hope for treating cutaneous T-cell lymphoma, potentially improving lives by addressing an unmet medical need in rare diseases.
Soligenix's clinical trial shows a 48% response rate, nearly double expectations, yet the stock market remains surprisingly subdued according to analyst reports.
Found this article helpful?
Share it with your network and spread the knowledge!
The article discusses Soligenix Inc. receiving a strong vote of confidence from Zacks Small-Cap Research regarding its clinical trial progress for HyBryte™, despite the stock market showing minimal reaction to the company's milestone achievement.
Soligenix reached 50-patient enrollment in its ongoing confirmatory Phase 3 FLASH2 trial for HyBryte™, which is used to treat cutaneous T-cell lymphoma, with an overall blinded response rate of 48% for patients who have completed treatment.
Zacks Small-Cap Research maintains a $25 per share valuation for Soligenix based on a probability-adjusted discounted cash flow model that considers potential future revenues.
The report indicates strong conviction about Soligenix's clinical results and enrollment milestone while expressing puzzlement at the market's subdued response, suggesting investors might be missing something significant.
The interim analysis is scheduled to occur in the second quarter of 2026, with the company currently having enrolled 50 patients out of a planned 80-patient study.
HyBryte™ is being developed for the treatment of cutaneous T-cell lymphoma, a rare disease where there is an unmet medical need.
Soligenix is a New Jersey-based biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need.
The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.
Curated from InvestorBrandNetwork (IBN)
